The Telehealth for Opioid Use Disorder Toolkit: Guidance to Support High-Quality Care, released in October 2021, focuses on buprenorphine (typically formulated as buprenorphine/naloxone, hereafter termed buprenorphine) and adjunctive psychotherapy treatment options for OUD and does not cover methadone treatment or XR-naltrexone. The primary goal of this toolkit is to provide clinically relevant information to support […]
SAMHSA has published a series of Advisories based on existing Treatment Improvement Protocols (TIPs) and Technical Assistance Publications (TAPs). These Advisories summarize updated guidance and recommendations on topics in the substance use disorder (SUD) treatment field. Check them out here.